

Medical Care Costs Associated with Cancer Survivorship

Cancer Epidemiology Biomarkers and Prevention
29, 1304-1312

DOI: [10.1158/1055-9965.epi-19-1534](https://doi.org/10.1158/1055-9965.epi-19-1534)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation. <i>Annals of Internal Medicine</i> , 2020, 173, 331-341.	2.0	24
2	A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 807-815.	1.1	2
3	A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 507-515.	1.1	6
4	A framework for cancer health economics research. <i>Cancer</i> , 2021, 127, 994-996.	2.0	5
5	Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87.	1.0	10
6	Cost Savings Associated With Palliative Care Among Older Adults With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1250-1257.	0.8	10
7	Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017-2030. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 79-92.	0.7	23
8	Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1670-1682.	3.0	97
9	Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study. <i>World Journal of Men's Health</i> , 2021, 39, 158.	1.7	6
10	Cancer Care Under the Biden Administration. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 527.	3.8	1
11	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
12	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 793-799.	0.6	11
13	Costs of Robotic-Assisted Radical Prostatectomy 1 Year After Surgery. <i>JAMA Network Open</i> , 2021, 4, e212548.	2.8	1
14	Assessing the relationship between symptoms and health care utilization in colorectal cancer survivors of different sexual orientations. <i>Supportive Care in Cancer</i> , 2021, 29, 5821-5830.	1.0	4
15	Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response. <i>Frontiers in Oncology</i> , 2021, 11, 626463.	1.3	30
16	Financial Toxicity in Adolescent and Young Adult Cancer Survivors: Proposed Directions for Future Research. <i>Journal of the National Cancer Institute</i> , 2021, 113, 948-950.	3.0	12
17	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.	1.4	7
18	Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer. <i>Health Affairs</i> , 2021, 40, 763-771.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Characterizing online crowdfunding campaigns for patients with kidney cancer. <i>Cancer Medicine</i> , 2021, 10, 4564-4574.	1.3	13
20	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2112878.	2.8	2
21	Impact of lay navigation on utilization and Medicare spending for cancer survivors in the Deep South. <i>Journal of Cancer Survivorship</i> , 2022, 16, 705-713.	1.5	3
22	Medical Cost of Cancer Care for Privately Insured Children in Chile. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6746.	1.2	3
23	Cancer Incidence Projections in the United States Between 2015 and 2050. <i>Preventing Chronic Disease</i> , 2021, 18, E59.	1.7	72
24	Microarrays and NGS for Drug Discovery. , 0, , .		0
25	Health state utility values by cancer stage: a systematic literature review. <i>European Journal of Health Economics</i> , 2021, 22, 1275-1288.	1.4	17
26	Association of Breast Cancer Screening Behaviors With Stage at Breast Cancer Diagnosis and Potential for Additive Multi-Cancer Detection via Liquid Biopsy Screening: A Claims-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 688455.	1.3	4
27	Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA. <i>Future Oncology</i> , 2021, 17, 3941-3950.	1.1	7
28	Support policies that foster a healthy food environment and incentivize healthy food purchases to mitigate cancer inequities. <i>Translational Behavioral Medicine</i> , 2021, , .	1.2	2
29	Association of Teaching Status and Mortality After Cancer Surgery. <i>Annals of Surgery Open</i> , 2021, 2, e073.	0.7	4
30	Capturing the Rest: Inpatient Mammography for Nonadherent Hospitalized Women. <i>American Journal of Preventive Medicine</i> , 2021, 61, 709-715.	1.6	3
31	Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	9
32	Current State of Health Economic Analyses for Low-Grade Glioma Management: A Systematic Review. <i>World Neurosurgery</i> , 2021, 152, 189-197.e1.	0.7	3
33	Psychosocial protective interventions associated with a better quality of life and psychological wellbeing for African American/Black female breast cancer survivors: an integrative review. <i>Supportive Care in Cancer</i> , 2021, , 1.	1.0	2
34	Differences in Cancer Care Expenditures and Utilization for Surgery by Hospital Type Among Patients With Private Insurance. <i>JAMA Network Open</i> , 2021, 4, e2119764.	2.8	7
35	Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. <i>British Journal of Cancer</i> , 2021, 125, 1432-1442.	2.9	41
36	Association of obesity and annual health care utilization and spending among long-term cancer survivors. <i>Cancer</i> , 2021, 127, 4675-4686.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice, 2022, 18, e129-e136.	1.4	4
38	Computational Approaches for Cancer-Fighting: From Gene Expression to Functional Foods. Cancers, 2021, 13, 4207.	1.7	2
39	Trends of hospitalizations among patients with both cancer and dementia diagnoses in New York 2007-2017. Healthcare, 2021, 9, 100565.	0.6	3
40	NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High-Quality Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1021-1026.	2.3	1
41	Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. Journal of Alzheimer's Disease, 2021, 83, 1563-1601.	1.2	8
42	Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. Value in Health, 2021, 25, 69-76.	0.1	2
43	Health care costs for adolescents and young adults with cancer: a Wisconsin community-based hospital study between 2005 and 2020. Supportive Care in Cancer, 2022, 30, 1703-1713.	1.0	4
44	Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and AFACT trials. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1367-1375.	0.5	2
45	Navigating the high costs of cancer care: opportunities for patient engagement. Future Oncology, 2021, 17, 3729-3742.	1.1	8
46	Addressing Cancer Financial Hardship Begins With Comprehensive Assessment of Patient Economic Burden. Journal of the National Cancer Institute, 2021, 113, 1606-1607.	3.0	1
47	Cancer treatment in the USA: a financially toxic cocktail. Nature Cancer, 2020, 1, 1136-1139.	5.7	2
48	COVID-19, Social Justice, and Clinical Cancer Research. Journal of the National Cancer Institute, 2021, 113, 1281-1284.	3.0	15
49	Exploring Middle School Students's Perspectives on Using Serious Games for Cancer Prevention Education: Focus Group Study. JMIR Serious Games, 2022, 10, e31172.	1.7	1
50	Assessment of MRI-Linac Economics under the RO-APM. Journal of Clinical Medicine, 2021, 10, 4706.	1.0	5
51	Understanding and Addressing Cancer Care Costs in the United States. JAMA Network Open, 2021, 4, e2127964.	2.8	3
53	CORR Insights®: Do Cohabitants Reliably Complete Questionnaires for Patients in a Terminal Cancer Stage When Assessing Quality of Life, Pain, Depression, and Anxiety?. Clinical Orthopaedics and Related Research, 2021, 479, 802-804.	0.7	0
54	Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology, 2022, 18, 363-373.	1.1	2
55	Cyanobacteria derived compounds: Emerging drugs for cancer management. Journal of Basic Microbiology, 2022, 62, 1125-1142.	1.8	4

#	ARTICLE	IF	CITATIONS
56	Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed. <i>Journal of the National Cancer Institute</i> , 2022, 114, 353-360.	3.0	25
57	Nurse-Led Telephonic Symptom Support for Patients Receiving Chemotherapy. <i>Oncology Nursing Forum</i> , 2020, 47, E199-E210.	0.5	1
58	The Impact of Health Delivery Integration on Cancer Outcomes. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 91-108.	0.6	1
59	Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1829.	3.8	34
60	Financial toxicity in cancer care: origins, impact, and solutions. <i>Translational Behavioral Medicine</i> , 2021, 11, 2043-2054.	1.2	50
61	Spending outcomes among patients with cancer in accountable care organizations 4 years after implementation. <i>Cancer</i> , 2021, , .	2.0	2
62	Medicare Spending, Utilization, and Quality in the Oncology Care Model. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1805.	3.8	4
63	Potential of Vitamin D Food Fortification in Prevention of Cancer Deaths—A Modeling Study. <i>Nutrients</i> , 2021, 13, 3986.	1.7	7
64	Development of the Oncology Opportunity Cost Assessment Tool: Item Generation and Content Validity Testing. <i>JCO Oncology Practice</i> , 2022, 18, e360-e371.	1.4	4
65	Healthcare Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	1
66	Adult oncology patients's™ experiences of living with a central venous catheter: a systematic review and meta-synthesis. <i>Supportive Care in Cancer</i> , 2022, 30, 3773-3791.	1.0	4
67	A History of Health Economics and Healthcare Delivery Research at the National Cancer Institute. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 21-27.	0.9	2
69	Think Globally, Start Locally: Value-Based Breast Cancer Care for Newly Diagnosed Patients in A Safety-Net Medical Center. <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
70	Financial distress and its associated burden in couples coping with an advanced cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 4485-4495.	1.0	6
71	Workforce Caring for Cancer Survivors in the United States: Estimates and Projections of Use. <i>Journal of the National Cancer Institute</i> , 2022, 114, 837-844.	3.0	4
72	Industry engagement: Accelerating discovery, application, and adoption through industry partnerships. <i>Cancer</i> , 2022, 128, 918-926.	2.0	2
73	A comparative study using time-driven activity-based costing in single-fraction breast high-dose rate brachytherapy: An integrated brachytherapy suite vs. decentralized workflow. <i>Brachytherapy</i> , 2022, , .	0.2	4
74	Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
75	Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 51-56.	0.9	6
76	Health Economics Research in Cancer Screening: Research Opportunities, Challenges, and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 42-50.	0.9	7
77	Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 735-741.	0.7	2
78	Financing Alzheimer's Disease Drug Development. , 2022, , 465-479.		1
79	De-implementing low-value care in cancer care delivery: a systematic review. Implementation Science, 2022, 17, 24.	2.5	13
80	Expanding oncology pharmacist teams: Justifying the return on investment. Journal of Oncology Pharmacy Practice, 2022, 28, 1381-1387.	0.5	2
81	Application of additively manufactured 3D scaffolds for bone cancer treatment: a review. Bio-Design and Manufacturing, 2022, 5, 556-579.	3.9	12
82	Opportunities and Challenges of Defining "Value" in Oncology Care. Annals of Surgical Oncology, 2022, , 1.	0.7	0
83	Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis. Annals of Translational Medicine, 2022, 10, 352-352.	0.7	0
84	Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Current Medical Research and Opinion, 2022, 38, 1285-1294.	0.9	9
85	Effect of inpatient breast cancer education and risk assessment on mammography utilization among hospitalized women post discharge. Hospital Practice (1995), 2022, 50, 132-137.	0.5	0
86	Cost-effectiveness of Robotic-Assisted Prostatectomy in the UK "Are We Doing Enough?. JAMA Network Open, 2022, 5, e225747.	2.8	3
87	A Patient-Centered Approach to Research Prioritization in Prostate Cancer. Journal of Urology, 2022, 208, 277-283.	0.2	2
88	Ketogenic diet and cancer: Fad or fabulous?. Journal of Parenteral and Enteral Nutrition, 2021, 45, 26-32.	1.3	5
89	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	0.7	20
90	Financial Hardship and Quality of Life Among Patients With Advanced Cancer Receiving Outpatient Palliative Care. Cancer Nursing, 2023, 46, 3-13.	0.7	2
91	Oncology Registered Dietitian Nutritionists' Knowledge, Attitudes, and Practices Related to Food Insecurity among Cancer Survivors: A Qualitative Study. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 2267-2287.	0.4	2
92	Health Economics Research in Primary Prevention of Cancer: Assessment, Current Challenges, and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 28-41.	0.9	4

#	ARTICLE	IF	CITATIONS
93	Cancer Screening Prevalence and Associated Factors Among US Adults. <i>Preventing Chronic Disease</i> , 2022, 19, E22.	1.7	18
94	Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5387-5397.	0.7	6
95	Fertility Preservation and Financial Hardship among Adolescent and Young Adult Women with Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1043-1051.	1.1	12
96	Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice. <i>Journal of Comparative Effectiveness Research</i> , 2022, , .	0.6	2
97	Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 437-453.	157.7	73
98	Digital Health Applications in Oncology: An Opportunity to Seize. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1338-1339.	3.0	8
99	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. <i>PLoS ONE</i> , 2022, 17, e0268584.	1.1	5
100	Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries. <i>JAMA Health Forum</i> , 2022, 3, e221229.	1.0	19
101	A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 977-988.	0.4	2
102	A Novel Approach to Modeling and Forecasting Cancer Incidence and Mortality Rates through Web Queries and Automated Forecasting Algorithms: Evidence from Romania. <i>Biology</i> , 2022, 11, 857.	1.3	7
103	Expected Cost Savings from Low Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada. <i>JTO Clinical and Research Reports</i> , 2022, , 100350.	0.6	1
104	Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 2103-2128.	2.6	16
105	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	2.8	27
106	A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
107	Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, .	0.6	4
108	Breast Cancer Survivor Risk of Respiratory Depression Associated with Gabapentin and Opioids. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
109	Carbon Nanotubes in Tumor-Targeted Chemotherapeutic Formulations: A Review of Opportunities and Challenges. <i>ACS Applied Nano Materials</i> , 2022, 5, 8649-8679.	2.4	6
110	Automated Notification of Relevant Expected or Incidental Findings in Imaging Exams in a Verticalized Healthcare System. <i>Journal of Medical Systems</i> , 2022, 46, .	2.2	1

#	ARTICLE	IF	CITATIONS
111	â€˜At All Costsâ€™™: Breast Cancer Patient Responses to Cost Transparency and Communication. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
112	Supervised and Non-Supervised Exercise Programs for the Management of Cancer-Related Fatigue in Women with Breast Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 3428.	1.7	5
113	Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. <i>Cancer Gene Therapy</i> , 2022, 29, 1975-1987.	2.2	6
114	The population-level economic burden of liver cancer in China, 2019â€“2030: prevalence-based estimations from a societal perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	6
115	Value-Based Care in Systemic Therapy: The Way Forward. <i>Current Oncology</i> , 2022, 29, 5792-5799.	0.9	3
116	End-of-Life Costs of Cancer Patients With Alzheimer's Disease and Related Dementias in the U.S.. <i>Journal of Pain and Symptom Management</i> , 2022, , .	0.6	0
117	Cost-analysis comparison of clinical risk assessment with and without ROMA for the management of women with pelvic masses. <i>Clinical Journal of Obstetrics and Gynecology</i> , 2022, 5, 080-089.	0.1	0
118	Financial toxicity in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1450-1454.	1.2	0
119	The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. <i>Advances in Therapy</i> , 2022, 39, 5025-5042.	1.3	5
120	Preventive Nutrition. <i>Medical Clinics of North America</i> , 2022, 106, 767-784.	1.1	1
121	Personâ€“years of life lost and lost earnings from cigarette smokingâ€“attributable cancer deaths, United States, 2019. <i>International Journal of Cancer</i> , 2022, 151, 2095-2106.	2.3	7
122	Compliance of National Cancer Instituteâ€“Designated Cancer Centers With January 2021 Price Transparency Requirements. <i>JAMA Surgery</i> , 2022, 157, 959.	2.2	2
123	Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 845-856.	1.0	2
124	Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI Data. <i>Diagnostics</i> , 2022, 12, 2102.	1.3	3
125	Increased healthcare costs by later stage cancer diagnosis. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	12
126	Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1392-1399.	3.0	12
127	Longitudinal patterns and predictors of healthcare utilization among cancer patients on home-based palliative care in Singapore: a group-based multi-trajectory analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
128	Prostate cancer aggressiveness and financial toxicity among prostate cancer patients. <i>Prostate</i> , 2023, 83, 44-55.	1.2	3

#	ARTICLE	IF	CITATIONS
129	Socioeconomic and insurance-related disparities in disease-specific survival among patients with metastatic bone disease. <i>Journal of Surgical Oncology</i> , 2023, 127, 159-173.	0.8	3
130	Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 997-1004.e3.	2.3	3
131	Comparison of three guidelines for screening, diagnosis and staging of prostate cancer in the USA and Europe. <i>Journal of Cancer Prevention & Current Research</i> , 2021, 12, 65-72.	0.1	0
132	Application of Drug Repurposing-Based Precision Medicine Platform for Leukaemia Patient Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2022, , .	0.8	0
133	Costs attributable to <i>Clostridioides difficile</i> infection based on the setting of onset. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	4
134	Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 1577-1589.	0.8	12
135	Two fully automated data-driven 3D whole-breast segmentation strategies in MRI for MR-based breast density using image registration and U-Net with a focus on reproducibility. <i>Visual Computing for Industry, Biomedicine, and Art</i> , 2022, 5, .	2.2	4
136	Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. <i>Cancers</i> , 2022, 14, 5365.	1.7	6
137	Empirical Dietary Patterns Associated with Food Insecurity in U.S. Cancer Survivors: NHANES 1999–2018. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14062.	1.2	1
138	Comparative cost savings of biosimilar and dose rounding utilization in oncology care. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211342.	0.5	0
139	Quantifying Total and Out-of-Pocket Costs Associated With Head and Neck Cancer Survivorship. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 1111.	1.2	5
140	Paying for Cancer Drugs—Getting What We Are (Prohibited From) Bargaining for. <i>JAMA Internal Medicine</i> , 0, , .	2.6	1
141	Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies. <i>Journal of Clinical Medicine</i> , 2022, 11, 6254.	1.0	2
142	Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 1215-1222.e1.	2.3	0
143	Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	1
144	Yoga Therapy During Chemotherapy for Early-Stage and Locally Advanced Breast Cancer. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211372.	0.8	1
145	Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. <i>JAMA Network Open</i> , 2022, 5, e2244204.	2.8	2
146	Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2327-2337.e9.	2.4	3

#	ARTICLE	IF	CITATIONS
147	Radiotherapy expenditures through the first eight performance periods of the Oncology Care Model at a statewide multispecialty health system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	1
148	Financial hardship and mental health among cancer survivors during the COVID-19 pandemic: An analysis of the US COVID-19 Household Impact Survey. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
149	Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. <i>Journal of Clinical Oncology</i> , 2023, 41, 2020-2028.	0.8	2
150	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
151	Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. <i>Future Oncology</i> , 2022, 18, 3895-3912.	1.1	12
152	Early circulating tumor <sc>DNA</sc> dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. <i>Molecular Oncology</i> , 2023, 17, 298-311.	2.1	7
153	Self-Healing Electronics for Prognostic Monitoring of Methylated Circulating Tumor DNAs. <i>Advanced Materials</i> , 2023, 35, .	11.1	7
154	Financial Toxicity in the Post-Health Reform Era. <i>Journal of the American College of Radiology</i> , 2023, 20, 10-17.	0.9	4
155	Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1260-1260.	0.7	0
156	Trends in Episode-of-Care Spending for Cancer-Directed Surgery Among US Medicare Beneficiaries From 2011 to 2019. <i>JAMA Surgery</i> , 0, , .	2.2	1
157	Financial Toxicity: A Barrier to Achieving Health Equity in Cancer Care. <i>Journal of the American College of Radiology</i> , 2023, 20, 37-39.	0.9	3
158	Relationship between mental health disorder symptoms and negative cancer perceptions among U.S. adults. <i>Cancer Causes and Control</i> , 2023, 34, 295-305.	0.8	0
159	Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 729-735.	0.4	2
160	Analysis of Artificial Intelligence in Medical Sectors. , 2022, , .		1
161	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. <i>Cancers</i> , 2023, 15, 689.	1.7	5
162	Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. <i>JCO Oncology Practice</i> , 2023, 19, e600-e617.	1.4	3
163	Role of Glucosamine and Chondroitin in the Prevention of Cancer: A Meta-Analysis. <i>Nutrition and Cancer</i> , 2023, 75, 785-794.	0.9	1
164	The use of gabapentinoids and opioids and risk of developing opioid-induced respiratory depression among older breast cancer survivors with neuropathic pain. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	3

#	ARTICLE	IF	CITATIONS
165	Area-level Socioeconomic Disadvantage and Cancer Survival in Metropolitan Detroit. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 387-397.	1.1	3
166	Incremental Health Care Costs of Anxiety and Depression Among Medicare Beneficiaries With Cancer. <i>JCO Oncology Practice</i> , 2023, 19, e660-e671.	1.4	2
167	A qualitative analysis of cancer-related patient care in the emergency department. <i>Academic Emergency Medicine</i> , 2023, 30, 842-850.	0.8	1
168	Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 511-531.	1.1	3
169	Chronic Diseases and Their Social Importance. , 2023, 3, 103-108.		0
170	Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High-Risk Features. <i>Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.1	1
173	Excess body fatness and cancer risk: a summary of the epidemiologic evidence. <i>Surgery for Obesity and Related Diseases</i> , 2023, 19, 742-745.	1.0	2
175	Liquid biopsies: the future of cancer early detection. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	45
176	Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311576.	0.5	0
177	<i>Coverage and Cost-of-Care</i> Links: Addressing Financial Toxicity Among Patients With Hematologic Cancer and Their Caregivers. <i>JCO Oncology Practice</i> , 2023, 19, e696-e705.	1.4	7
178	Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study. <i>PLoS ONE</i> , 2023, 18, e0269079.	1.1	0
179	Effects of periodontitis on cancer outcomes in the era of immunotherapy. <i>The Lancet Healthy Longevity</i> , 2023, 4, e166-e175.	2.0	2
180	Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021. <i>Clinical Drug Investigation</i> , 2023, 43, 289-298.	1.1	5
181	Transcriptomic reprogramming for neuronal age reversal. <i>Human Genetics</i> , 0, , .	1.8	3
182	The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping review. <i>Cancer Causes and Control</i> , 2023, 34, 407-420.	0.8	10
183	Therapeutic Potential of Clostridium novyi-NT in Cancer: Current Knowledge and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2023, 23, 682-696.	0.8	1
184	Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions. <i>Journal of Clinical Oncology</i> , 2023, 41, 3051-3058.	0.8	10
185	Suicidal Ideation Among Patients with Gastrointestinal Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 3929-3938.	0.7	4

#	ARTICLE	IF	CITATIONS
232	Comprehensive and User-Analytics-Friendly Cancer Patient Database for Physicians and Researchers. , 2022, , .		0
247	Dose-reduction trials in oncology â€” aiming for less toxicity and better quality of life at lower costs. Nature Reviews Clinical Oncology, 0, , .	12.5	0
249	Disparities in Neuro-Oncology. Current Neurology and Neuroscience Reports, 2023, 23, 815-825.	2.0	1
263	The Economic Impact of COVID-19 on Dermatology. Updates in Clinical Dermatology, 2023, , 167-181.	0.1	0
278	Assessing the Risk of Heavy Metal Mixture Exposure and its Association with Cancer Mortality. , 2023, , .		0
285	Patients and Trust: The Impact of Advocacy to Advance Patient-Centered Care. Psychiatry Update, 2024, , 117-127.	0.1	0